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Summary Photodynamic therapy (PDT) is a promising technique for the treatment of small tumours in
organs where it is essential to minimise damage to immediately adjacent normal tissue as PDT damage to many
tissues heals by regeneration rather than scarring. As preservation of function is one of the main aims of
treating laryngeal tumours, this project studied the effects of PDT on the normal rabbit larynx with two
photosensitisers, endogenous protoporphyrin IX (PPIX) induced by the administration of 5-aminolaevulinic
acid (ALA) and disulphonated aluminium phthalocyanine (AlS2Pc). The main aims of the study were to
examine the distribution of protoporphyrin IX and AlS2Pc by fluorescence microscopy in the different regions
of the larnyx and to assess the nature and subsequent healing of PDT damage. Peak levels of PPIX were found
0.5-4 h after administration of ALA (depending on dose) with highest levels in the epithelium of the mucosa.
With 100 mg kg-', PDT necrosis was limited to the mucosa, whereas with 200 mg kg-l necrosis extended to
the muscle. With 1 mg kg - AlS2Pc, 1 h after administration, the drug was mainly in the submucosa and
muscle, whereas after 24 h, it was predominantly in the mucosa. PDT at 1 h caused deep necrosis whereas at
24 h it was limited to the mucosa. All mucosal necrosis healed by regeneration whereas deeper effects left some
fibrosis. No damage to cartilage was seen in any of the animals studied. The results of this study have shown
that both photosensitisers are suitable for treating mucosal lesions of the larynx, but that for both it is
important to optimise the drug dose and time interval between drug and light to avoid unacceptable changes in
normal areas.
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Conventional management of malignant laryngeal tumours is
by surgery or radiotherapy. Early tumours can be treated
endoscopically by laser surgery or conventional techniques,
which can be repeated for persistent or recurrent lesions, but
there is always a difficult balance between removing enough
tumour to minimise the risk of recurrence and leaving as
much normal tissue as possible to optimise function. There is
usually some deterioration in the quality of the voice after
treatment. In the UK and North America, radiotherapy is the
treatment of choice for early tumours. This induces little or
no damage to the voice, but because of cumulative toxicity, it
is often not possible to repeat it for any local recurrence. For
early tumours, the 5 year survival rate for each method is
80-90% (Kleinsasser, 1987). Thus the preservation of the
voice becomes a particularly important aspect of treatment.
A new non-surgical technique which could destroy tumours
of the larynx without the cumulative toxicity of ionising
radiation and avoid destroying normal parts of the larynx
with the consequent disturbance of voice function could
represent a valuable advance. Photodynamic therapy (PDT)
produces localised tissue necrosis with light following prior
administration of a photosensitising drug. Although the
tumour selectivity of PDT is often overemphasised, it is
now well documented that PDT necrosis of many normal
tissues heals with regeneration rather than scarring. This
makes it a promising approach for treating small tumours in
many organs.
Photodynamic therapy (PDT) of head and neck tumours
has attracted increasing attention over the last ten years, as
shown by more than 30 recent clinical publications (Gluck-
man, 1991; Feyh et al., 1993). However, despite the inherent
suitability of PDT for laryngeal tumours, only a few studies
have been performed on this organ to date (Gluckmann and
Weissler, 1986; Wustrow et al., 1988, 1989; Abramson et al.,
1990, 1992; Feyh et al., 1990; Freche and De Corbiere, 1990;
Kleemann, 1990; De Corbiere et al., 1992; Feyh, 1992; Biel,
1994). The easier access to other parts of the head and neck
region such as the oral cavity may partly account for this
comparative neglect. Nevertheless, PDT is promising as a
function-preserving treatment, especially for small laryngeal
malignancies, precancerous lesions of the larynx and lesions
like laryngeal papillomatosis. Haematoporphyrin derivative
(HpD) and its derivatives like Photofrin are currently the
most widely studied photosensitisers undergoing clinical
trials. Although good results using these sensitisers have
been reported (Monnier et al., 1990; Abramson et al., 1992;
De Corbiere et al., 1992; Feyh, 1992; Grant et al., 1993a;
Biel, 1994), they have certain disadvantages, particularly the
long-lasting skin photosensitivity, which has prompted an
active search for new photosensitisers with more suitable
properties.
Two agents that have attracted much recent interest are
endogeneous protoporphyrin IX induced by administration
of exogenous 5-aminolaevulinic acid (ALA) and disulpho-
nated aluminium phthalocyanine (AlS2Pc). ALA is a
naturally occurring haem precursor whose production is
regulated by the level of haem through a negative feedback
mechanism acting on ALA synthase (Rimington, 1966;
Marriott, 1968). Using excess amounts of exogenous ALA,
this feedback control can be bypassed which leads to the
build up of protoporphyrin IX (PPIX) with the final step
converting PPIX to haem then becoming the rate-limiting
step. PPIX is an active photosensitiser and thus any cell
capable of synthesising haem can be sensitised by this means.
Photodynamic effects have been produced both in vitro and in
vivo after ALA administration and subsequent exposure to
red light at 630 nm (Malik and Lugaci, 1987; Divaris et al.,
1990). Compared with HpD, the great advantage of ALA is
the short duration of tissue sensitisation, especially the skin
(typically less than 24 h). More recently, several experimental
and clinical studies using ALA have been reported showing
that, unlike other currently available photosensitisers, it can
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be given either topically or systemically (orally or intrave-
nously), (Kennedy et al., 1990; Wolf and Kerl, 1991;
Kennedy and Pother, 1992; Bedwell et al., 1992; Loh et al.,
1992; Peng et al., 1992; Loh et al., 1993a; Grant et al.,
1993b). AlS2Pc has been reported to be a potent photo-
sensitiser by several groups (Paquette et al., 1988; Berg et al.,
1989; Chan et al., 1990; Chatlani et al., 1991; Meyer et al.,
1991; Loh et al., 1992). It is biologically similar to HpD, but
causes much less skin photosensitivity (Tralau et al., 1989).
PDT necrosis of squamous cell carcinomas, the most
common tumour of the larynx, is well documented (Wustrow
et al., 1988, 1989; Feyh et al., 1990, 1993; De Corbiere et al.,
1992; Biel, 1994). However, for PDT to be of clinical value it
is essential for the nature of the damage and subsequent
healing of necrosed tumour and necrosed adjacent normal
tissues to be fully understood. This is of particular
importance in an organ such as the larynx whose function
is very sensitive to small changes in its component tissues.
Abramson et al. (1990) carried out PDT experiments on the
normal canine larynx using HpD. They described macro-
scopic changes and thermal effects and advised the use of
light doses no higher than 100 J cm-2 to avoid laryngeal
obstruction after PDT. Chevretton et al. (1992) described
studies of PDT effects on normal striated muscle and showed
that at least some regeneration and restoration of function is
possible after PDT necrosis. Other investigators have
provided further information on PDT on normal tissues in
a range of organs using ALA and AlS2Pc (Meyer et al., 1991;
Nuutinen et al., 1991; Pope and Bown, 1991; Bedwell et al.,
1992; Judd et al., 1992; Loh et al., 1992, 1993a).
The aims ofthis study were to use fluorescence microscopy



























laryngeal tissues (mucosa, submucosa, muscle and cartilage),
and to assess the damage and subsequent healing of these
tissues following exposure to red light in sensitised animals.
The hope was that we could achieve mucosal necrosis reliably
without unacceptable damage to the underlying submucosa
and muscle, which has not previously been shown using PDT
on the larynx. The main aim was to study ALA. The limited
number of experiments done with AlS2Pc were to provide a
comparison between sensitisers and to make it easier to
correlate the ALA results with our previous extensive studies
with the phthalocyanines (Meyer et al., 1991; Nuutinen et al.,
1991; Pope and Bown, 1991; Smith et al., 1993).We chose the
rabbit larynx as the experimental model for this work, as the
rabbit was considered to be the smallest animal with a larynx
of suitable structure and size for these experiments.
Materials and methods
5-Aminolaevulinic acid (ALA) was obtained from the Sigma
Chemical Company (Poole, UK); it was dissolved in sterile
saline and buffered with sodium bicarbonate to pH 5 shortly
before intravenous administration at a concentration of
80 mg ml-'. AlS2Pc was prepared in the Department of
Chemistry, Imperial College, London (Bishop et al., 1993). It
was dissolved in 0.1 M NaOH and buffered to PH 7.4 for
intravenous administration giving a final concentration of
1 mg ml-'.
A total of 73 male New Zealand white rabbits was used in
this project. These were divided into two groups. The first
group of 40 animals was used for pharmacokinetic studies
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Figure 1 Mean level of fluorescence (±s.d.) of laryngeal tissues measured by fluorescence microscopy after i.v. administration of
200 mgkg- 1 ALA as a function oftime: (a) mucosa, (b) submucosa, (c) muscle, (d) cartilage. The value at each time point represents
the mean (with standard deviation) of measurements from two or three animals and three different areas for each tissue in each
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intravenous injection into an ear vein under light sedation
with Hypnorm (fentanyl and fluanisone). Animals were
sensitised with 200. 100 or 20 mg kg-' body weight ALA
or 1 mg kg-' AlS2Pc. These doses were chosen on the basis
of previous results from this centre on other organs as
described above. Two or three animals per time point were
killed from 0.5 h up to 1 week after ALA injection. The
larynx was removed at post mortem. and frozen immediately
in isopentane cooled in liouid nitrogen. Frozen sections of
10pum thickness were cut and stored at -20-C before
analysis. In view of our extensive previous studies with
AlS,Pc (Nuutinen et al.. 1991: Smith et al.. 1993), only two
time points (1 h and 24 h) after sensitisation were chosen to
determine the AlS.Pc distribution. Quantitative fluorescence
imaging of the frozen sections was carnred out with a
fluorescence microscope (Olympus IMT-2). attached to a
CCD (charge-coupled device) camera system (Wright
Instruments. Cambnrdge. UK) as described preViously
(Chan et al.. 1989: Bedwell et al.. 1992: Loh et al.. 1992).
Images were recorded using a 10 x objective: the low-power
composite images were composed from three adjacent areas.
All fluorescence measurements were corrected for autofluor-
escence as measured on control specimens from unsensitised
animals. After fluorescence microscopy. slides were fixed in
formalin and stained with haematoxylin and eosin. The light
microscopy image and the fluorescence image (falsely colour-
coded for ease of analysis) were compared to correlate the
fluorescence distribution of the photosensitiser within the
tissue sections.
The second group of 33 animals underwent laser treatment
of the larynx. In all, 24 animals were given drug and light,
seven controls received light only. and in two further controls
only a tracheotomy was performed without drug orlight. The
relatively large number of light-only control animals was
owing to the need to optimise the light delivery technique.
Drug-only controls were taken from animals used in the
pharmacokinetic part of the study. The light source used was
a pulsed (12 kHz) copper vapour pumped dye laser (Oxford
Lasers. Oxford). For ALA the laser was tuned to 630 nm,
and for AlS.Pc. to 675 nm. For ALA. the time intervals
between drug and light were chosen on the basis of the
fluorescence pharmacokinetic experiments. Animals which
received 200 mg kg-' ALA were treated 4 h after sensitisa-
tion (n=9) and those receiving 100 mg kg ALA at 3 h
(n=6), to match the time of the peak mucosal fluorescence.
Four animals were sensitised with 20 mg kg-' ALA and
subsequently treated at several time points (30, 40, 50 and
90 mmn) as the optimum time was difficult to ascertain from
the pharmacokinetic studies. Up to three animals were
treated for each combination of drug dose and time from
light exposure to killing the animal to ensure that results were
reproducible. The times from PDT to killing the animal were
divided into early (24-48 h, intermediate (10 days) and late
(6 weeks). Animals given AlS2Pc (n =5) were treated 1 (n = 2)
or 24 h (n =3) after sensitisation. To minimise the number of
animals required, not all combinations of values were studied,
and for the less important combinations studied, only one
animal was used. No late studies were undertaken with
AlS.Pc as similar studies had been reported previously from
our group on rat trachea (Smith et al., 1993).
Laser treatment of the larynx was undertaken via a
tracheotomy performed under general anaesthesia with
Hypnorm and Diazepam. Covering one-half of the larynx
With a sheet of opaque paper (to reduce the risk of oedema
after treatment causing respiratory obstruction), the micro-
lens laser fibre (200 pm diameter, PDT Systems, USA) was
inserted through the trachea and fixed at a distance about
0.5-1.0 cm from the infenror aspect of the true vocal cord.
The laser spot size was adjusted to between 2.5 and 5 mm by
varying the distance from the fibre tip to the tissue so the
spot covered the true and the false vocal cord, the laryngeal
ventricle and the subglottic area nearest to the true vocal
cord. The exposure time was calculated from the power at the
fibre tip (set at 100 mW) and the distance from the tip to the
target tissue, to give a total light dose of 100 J cm- . The
actual exposure times used were in the range 600-900 s. This
same light dose of 100 J cm-Iwas used for all animals
treated in this study. At the end of laser treatment. the fibre
was removed. the tracheotomv closed and the animals
allowed to recover. Animals were observed twice a day and
any showing signs of respiratory difficulty were given
corticosteroids up to 48 h after treatment to avoid larvngeal
obstruction from oedema. This was required in all animals
given 200 mg kg-' ALA or I mg kg AlS2Pc but in only
onegiven 100 mg kg-' ALA. First signs were seen 4 h after
PDT and the maximum effect was seen at 24 h. With this
regime. none developed severe respiratorv distress. The
rabbits were kept under standard animal house conditions
until killed at various subsequent time points (24 h. 48 h. 10
days and 6 weeks). On killing the animal. the larynx was
excised immediately and opened longitudinally along the
posterior side for macroscopic inspection. The larynx was
fixed in 5% buffered formalin for at least 3 days and then cut
longitudinally. Representative tissue samples of the supra-
glottic. glottic and subglottic region were retrieved and
embedded in paraffin wax. Sections (4 gm thick) were cut
from each block and stained with haematoxylin and eosin
I
Figwe 2 (a) Composite low-power magnification fluorescence
image of frozen sections of a larynx cut horizontally 4h after
200mgkg- 1 ALA. The mucosal layer and submucosal glands are
brightly fluorescent with a moderate signal from cartilage and
very little from submucosa and muscle; (b) Photomicrograph of
the same section as in (a) after H&E staining; (c) Composite low-
power magnification fluorescence image of frozen sections of a
larynx cut horizontally Ih after 1 mgkg - AlS2Pc. All tissues
apart from cartilage show considerable fluorescence: (d) Photo-
micrograph of the same section as in (c) after H&E staining. (m.
mucosa; mus. muscle).
I
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(H & E), periodic acid Schiff (PAS) and with Masson's
trichrome for histological examination. The sections were
examined by two independent pathologists.
Results
Fluorescence microscopy
In the rabbit larynx, the mucosa is composed of the
epithelium and the underlying superficial connective tissues
(the lamina propria). Below this lies the submucosa which is
the fibro-fatty connective tissue deep to the lamina propria
which may contain mucous glands. In some areas the
mucosa is bound down tightly to the perichondrium or to
muscle so there is no submucosal layer. The distribution of
PPIX fluorescence after administration of 200 mg kg-' ALA
is shown in Figure 1. With this dose, the fluorescence signal
in the mucosa rose rapidly to a peak at 4 h (see Figures 2
and 3) whereas the signal in the other layers rose more
slowly and to lower peak levels. The highest levels were seen
in the epithelium of the mucosa with moderate levels in the
submucosal glands and little in the muscle or the lamina
propria. The ratio between mucosa and both submucosa and
muscle reached a maximum of approximately 7:1 at the
peak time of 4 h. In contrast, the signal in cartilage
increased at a much slower rate reaching a later maximum
at around 48 h. There was no detectable fluorescence in any
tissue after 1 week. The peak fluorescence in the mucosa was
achieved earlier with lower doses of ALA and declined more
rapidly as shown in Figure 4. Peak levels after 100 mg kg-'
were similar to those after 200 mg kg-, but were attained
1 h earlier. As a result, the ratio between mucosa and
cartilage at 3 h after 100 mg kg-' was 5:1 (data not shown),
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Figure 4 Mean fluorescence of laryngeal mucosa after different
doses of ALA as a function of time. Each point represents the
mean (with standard deviation) of three different areas per tissue
in two animals for each time point. All values have been corrected
for tissue autofluorescence.
Table I Levels of fluorescence in the layers of the larynx 1 and 24h
after 1 mgkg-1 AIS2Pc
Fluorescence intensity (±s.d.)/(counts per pixel)
Time (h) Mucosa Submucosa Muscle Perichondrium
1 33 (5) 90 (12) 38 (5) 25 (4)
24 22 (5) 25 (5) B B
B, indistinguishable from background readings.
I
Figure 3 High-power views of the same sections as in Figure 2. False colour-coded fluorescence images (white, highest intensity) of frozen
sections of a larynx cut horizontally and the corresponding H&E stains: (a) and (b) 4h after 200mgkg-1 ALA; (c) and (d) 1 h after
1 mgkg-l AlS2Pc. These images demonstrate the differences in the patterns ofmucosal and cartilage fluorescence after ALA and AlS2Pc. (m,
mucosa; s, submucosa; car, cartilage; m.g., mucous glands; mus, muscle).
^ AA 1The microscopic fluorescence intensity distributions at 1
and 24 h after 1 mg kg-' AlS2Pc are given in Table I. The
highest levels were seen in the submucosa at 1 h. The levels in
mucosa, muscle and cartilage (mainly perichondrium) were
Photodynamic therapy on normal larynx
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comparable with each other and lower than those found in
the submucosa (see Figures 2 and 3). The fluorescence levels
in all layers had declined significantly by 24 h. Little could be
detected in muscle and cartilage at this time, although there
Figure 5 Glottic region 48h after PDT given 3h after 100mgkg-1 ALA. There is complete epithelial necrosis with ulceration and
marked inflammation'of the superficial lamina propria (arrows). In contrast, there are only minimal inflammatory changes in the
underlying submucosa. There were no abnormalities in the muscle or cartilage (not shown in this section) (H & E).
IbF -'>g 't " a 'Y g- _s*,
Figure 6 (a) Glottic region 6 weeks after PDT given 4h after 200mgkg- 1 ALA. The epithelium has regenerated with proliferation
of the basal cell layer. There is inflammation with necrosis and developing fibrosis in the deep muscle layers (arrows). There is no
damage to cartilage (not shown in this section) (H & E). (b) Glottic region 6 weeks after PDT given 3h after 100mgkg ALA. The
epithelium has regenerated with proliferation of the basal cell layer. In contrast to the findings using 200mgkg-1, there is minimal
fibrosis in the subepithelial tissues, but no abnormalities in the deep muscle or cartilage.Photodynamic therapy on normal larynx
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was still moderate fluorescence in mucosa and submucosa,
the absolute levels in these layers being similar. A marked
difference in the fluorescence pattern of the cartilage was
found after AlS2Pc sensitisation compared with that after
ALA. Using AlS2Pc the fluorescence signal was mainly in the
perichondrium, whereas after ALA the highest signal was
seen in the chondrocytes with redistribution from an
intracellular location to the matrix occurring after 48 h.
Photodynamic therapy
Macroscopic changes No macroscopic lesions were seen in
the control groups treated with sensitiser alone, light alone or
those which just underwent a tracheotomy without any other
treatment. Using 200 mg kg-' ALA with PDT at the peak
time (4 h), extensive oedema of the irradiated side of the
larynx was apparent by 24 h after treatment and macroscopic
mucosal necrosis exceeding 5 mm in diameter by 48 h. With
100 mg kg-' ALA, less extensive lesions, comparable with
the size of the irradiated area (5 mm) were found. However,
with either dose, regenerated epithelium was found by 10
days. When the dose of ALA was reduced to 20 mg kg-', no
macroscopic lesions could be seen at any time after
treatment. After photosensitisation with 1 mg kg-' AlS2Pc
1 h before PDT, extensive injury to the treated side of the
larynx extending up to 3 mm beyond the laser irradiation
zone was seen in animals killed at 48 h. For animals treated
Figure 7 Glottic region 48h after PDT given 24h after
mgkg-1 AlS2Pc. There is extensive necrosis of the epithelium
although the basal layer appears intact (arrows). Inflammatory
cell infiltration of the muscle is present. In this region, the lamina
propria abuts directly onto the cartilage and there is no
submucosa (H & E).
24 h after sensitisation with the same dose, a smaller, well-
circumscribed lesion was found (typically about 5 mm in
diameter, matching the size of the light spot used for
illumination). If the dose was reduced to 0.5 mg kg-1
AlS2Pc with light exposure at 24 h, no macroscopic effect
was seen. By 10 days after PDT with the 1 mg kg-1 dose, the
larynges examined looked macroscopically normal.
Histology Untreated animals (drug only) and those withjust
a tracheotomy showed no histological changes. Those
exposed to laser light without prior sensitisation did show
some diffuse, inflammatory infiltration of the mucosa and
patchy inflammatory cell infiltration in deeper structures with
oedema and areas of haemorrhage 24 h after treatment.
However, these changes were mild and after 10 days, all that
could be seen was some minimal subepithelial fibrosis.
With the highest dose of ALA studied, (200 mg kg-1),
necrosis was seen down to the deep striated muscle by 48 h
after treatment. In contrast, with 100 mg kg-', the zone of
necrosis was confined to the mucosal layer and superficial
seromucous glands (Figure 5), with no necrosis of muscle. By
10 days the mucosa was regenerating in animals treated with
each dose, but with persistent deep necrosis in the
200 mg kg-1 group. Long-term results (6 weeks after
treatment) demonstrated re-epithelialisation of the true and
false vocal cords in both groups. In the group sensitised with
100 mg kg-' there was only moderate subepithelial fibrosis at
Figure 8 Glottic region 48 h after PDT given 1 h after 1 mgkg-1
AlS2Pc. There is focal necrosis of the epithelium with disruption
of the basal layer and extravasation of red cells in the lamina
propria. There is also muscle degeneration (arrow) and
inflammation of the deep perichondrium (arrowheads). There is
no submucosa in this area (H & E).Photodynamic therapy on normal larynx
D Kleemann et al
Table II Summary of histological changes after photodynamic therapy
Sensitiser Time interval Histology changes
and dose before light Early (24-48h) Intermediate (10 days) Late (6 weeks)
Tracheotomy only - None * *
Sensitiser only - None None *
(ALS2Pc or ALA)
Light only - SI+ + SF+ SF+
DI+
ALA 200mgkg' 4h SI+++ SN+++ SI+ + + SN+ + + SF+ + SF+ + +
DI+++ DN+++ DI+ + + DN+ + + DF+ + DN+ DF+ + +
ALA l00mgkg-' 3h SI+++ SN+++ SI+ SF++ SI+ SF++
DI+
ALA 20mgkg-1 30, 40, 50 and SI+ + SN+ * *
90min
ALS2Pc lmgkg lh SI+ + SN+ * *
DI+ + + DN+ + +
ALS2Pc lmgkg' 24h SI+++ SN+++ SF+± *
DI+ +
ALS2Pc 0.5mgkg-1 24h SI+ + SN+ * *
DI+
SI, Superficial inflammation; SN, Superficial necrosis; SF, Subepithelial fibrosis; DI, Deep inflammation; DN, Deep necrosis; DF,
Deep fibrosis. +, patchy changes; + +, moderate changes; + + +, severe changes. *No animals treated using these values.
this time, but with 200 mg kg-' , there was oedema and
inflammation associated with considerable fibrosis in the
muscle layer with no indication of muscle regeneration
(Figure 6a, b). With the low dose of ALA (20 mg kg-')
only mild and patchy changes were seen, limited to the
superficial regions.
Animals sensitised with 1 mg kg-' AlS2Pc 24 h before
PDT and killed 48 h later showed extensive superficial
epithelial necrosis with some inflammation in the deep
muscle (Figure 7). At the lower dose of 0.5 mg kg-', similar
changes were seen but were patchy. However, using
1 mg kg-' and the shorter time of 1 h between drug and
light, more extensive damage was seen in the deeper layers
with degeneration of muscle and marked perichondritis even
though the mucosal layer exhibited only focal epithelial
necrosis with some haemorrhage in the lamina propria
(Figure 8). Ten days after PDT (with the 24 h drug to light
interval), moderate and diffuse submucosal fibrosis and
reactive myofibroblastic proliferation were seen (much more
marked changes than were seen with laser alone).
There was no evidence of cartilage necrosis in any of the
sections examined with either photosensitiser. The histologi-
cal changes are summarised in Table II.
Discussion
The key to using a technique like PDT for treating lesions of
the larynx is to establish conditions under which diseased
areas can be destroyed and the adjacent normal tissue is
either unaffected or only undergoes changes that do not cause
any permanent impairment of laryngeal function. Much has
been written about the selectivity of PDT. There is good
evidence for some degree of selectivity in the uptake of
photosensitisers in neoplastic tissues in many organs between
tumour and the adjacent normal tissue in which the tumour
arose (Tralau et al., 1987), but very little evidence that this
selectivity of uptake can be used to achieve selective tumour
destruction. In special circumstances when the tissue
concentrations of photosensitiser are close to the threshold
levels for a PDT effect, it may be possible to have levels
above the threshold in tumour but below threshold in
adjacent normal tissue, but under these conditions it is
likely that the PDT effect will be very superficial (Barr et al.,
1990a). It is easier to get selectivity of necrosis between
different layers of normal tissue (e.g. mucosa and underlying
muscle, as in results reported by Pope and Bown (1991) in
the rat bladder and Loh et al. (1992) in the rat stomach) than
between neoplastic and normal mucosa. In practice, the main
selectivity of PDT is achieved by illuminating the tumour and
not adjacent normal tissues. However, all solid tumours must
meet normal areas somewhere, and in these sites, both will be
exposed to the same light dose. Apparent selectivity is seen
because there is necrosis to both normal and tumour tissues,
but healing in all areas is by regeneration of normal tissue.
Most solid tumours respond to PDT and take up slightly
more sensitiser than their normal tissue of origin, so in
assessing its potential in any tissue, the challenge is to see
what it does to the normal tissue and to understand how any
PDT-induced damage heals. The purpose ofthe present study
has been to look at the effects of PDT on all parts of the
normal rabbit larynx with two different sensitisers and
identify conditions under which PDT necrosis heals without
unacceptable sequelae. The photosensitisers used in this
study, ALA-induced PPIX and AlS2Pc, are known to have
different pharmacokinetics. PPIX accumulates intracellularly
and the PDT effect is directed mostly at mucosal cells (Loh et
al., 1992). AlS2Pc accumulates mainly in the microvascular
stroma of the submucosa (similar to HpD, Bugelski et al.,
1981) so the PDT effect is mainly on the microvasculature.
The two were contrasted to assess their potential for use in
the larynx. Use of fluorescence microscopy enabled us to
study their distribution in each layer of the larynx at a range
of times after administration before the PDT studies.
The accumulation ofPPIX after systemic administration of
ALA in epithelial tissues and epithelial tumours has been
reported by several authors (Divaris et al., 1990; Kennedy and
Pottier, 1992; Bedwell et al., 1992; Loh et al., 1992; Grant et
al., 1993b). Other tissues, particularly those of mesodermal
origin, such as muscle, submucosa and other connective tissues
have shown relatively little PPIX. We found similar results in
the larynx. However, the PPIX levels seen in cartilage were
unexpected and higher than previously reported from studies
ofmouse ear (Kennedy and Pottier, 1992). This peak was seen
considerably later than in other regions, only peripheral nerves
exhibiting similar kinetics (our own unpublished data and WE
Grant, personal communication). The results of varying the
dose of ALA were consistent with those reported in other
tissues (Loh et al., 1992); fluorescence maxima were seen at
earlier times with lower doses. Peak mucosal sensitisation was
seen about 1 h earlier using 100 mg kg-' (3h) than with
200 mg kg-' (4h) although similar kinetics for both doses
were found for cartilage.
Three main differences in the fluorescence patterns were
found between ALA and AlS2Pc. High levels of PPIX were
found in the mucosa at the early times after ALA in contrast
to the predominant localisation of AlS2Pc in the submucosa
1 h after sensitisation. No PPIX was detectable in the mucosaPhotodynamic therapy on normal larynx
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and submucosa at 24 h whereas AlS2Pc was detectable in
both layers at this time and thirdly, PPIX was detected within
chondrocytes whereas AlS2Pc was seen mainly in the
perichondrium with very low levels in cartilage itself.
In the PDT experiments three groups of control animals
were used - photosensitiser alone, tracheotomy alone and
laser irradiation alone. In the first two groups, no effects were
seen. No macroscopic signs were found after laser radiation
alone. However, some minor changes were found histologi-
cally which were not seen in the other control groups. The
simplest explanation is that these effects were thermal
although the fibre output was only 100 mW and the fibre
was not in contact with the tissue during irradiation.
Abramson et al. (1990) found little increase of tissue
temperature even with higher power densities. We did not
measure temperatures, but it is unlikely that there was a
significant rise. Some form of biostimulation is another
possibility, but the effects were minor and much less than
those seen in sensitised animals, and so are unlikely to be
relevant to the conclusions of this paper.
As the most important tumours of the larynx are
squamous cell carcinomas arising in the epithelial layer of
the mucosa, the time intervals between administration of
drug and light chosen for the PDT studies were those at
which peak levels of mucosal photosensitiser fluorescence
were seen. For ALA, this depended on the dose used. For
AlS2Pc, animals were treated both at 1 h and 24 h with 1 h
corresponding to the peak fluorescence and 24 h to the
optimum mucosa-submucosa fluorescence ratio reported in
other organs (Loh et al., 1992). Macroscopically, the main
worry after PDT of the larynx is that oedema in the treated
area will cause respiratory obstruction. These experiments
were limited to one side of the larynx, but marked oedema
was seen in some of the animals treated with higher sensitiser
doses. This reached a maximum 24 h after light exposure,
although some oedema was still present at 10 days. This
could be controlled easily with steroids and a human larynx
is somewhat larger than that of a rabbit, but this aspect will
require careful consideration in any clinical studies.
In this study, mucosa injured by PDT regenerated within a
relatively short time with both sensitisers. Damaged under-
lying tissues, particularly muscle, did not heal so well leading
to some scarring depending on the severity of the initial
insult, as has been reported in other organs (Meyer et al.,
1991; Pope and Bown, 1991; Bedwell et al., 1992; Loh et al.,
1992; Chevretton et al., 1992). With the highest dose of ALA
(200 mg kg-'), we found severe damage to mucosa,
submucosa and muscle. After 6 weeks, the mucosa had
regenerated completely, but intramuscular fibrosis persisted.
More selective damage was produced with 100 mg kg-1 ALA
with which necrosis was confined to the mucosal layer
although there was a strong inflammatory reaction in the
submucosa and muscle. Only superficial, patchy necrosis of
the mucosa was seen using 20 mg kg-' although it is possible
that a more uniform effect would have been seen with a
higher light dose.
With AlS2Pc and 24 h between sensitiser and light, the
pattern of PDT effects was broadly similar to the effects seen
with ALA, as would be expected with most of the sensitiser
being located in the mucosa rather than muscle at this time.
Using a dose of 1 mg kg-', necrosis was seen mainly in the
mucosa with some in the submucosa and none in muscle. In
contrast, with laser irradiation after just 1 h, the most severe
damage was seen in the muscle and submucosa. These
findings correlated well with the fluorescence microscopy
studies described above showing that the distribution of
fluorescence for both PPIX and AlS2Pc can be correlated
with their biological activity as photosensitisers. Although
Chevretton et al. (1992) described a reasonable restoration of
the function of striated muscle after severe damage by PDT
using HpD (haematoporphyrin derivative, which acts
biologically like AlS2Pc rather than ALA, Barr et al.,
1990b), their results may not be relevant to the larynx
which is so dependent on muscle for normal function. We did
not find any signs of active muscle regeneration as they
described with either sensitiser. A recent report by Biel et al.
(1994) using Photofrin with treatment 24-48 h after drug
administration described ablation of laryngeal tumours with
restoration of a normal voice by 6-8 weeks after treatment.
This is consistent with our conclusion that there is no serious
muscle damage with AlS2Pc if the drug to light interval is
24 h.
No definite necrosis in cartilage was seen with either
photosensitiser under any of the conditions used in this study,
despite the accumulation of PPIX in cartilage and the
perichondrial inflammation seen with AlS2Pc. It is possible
that damage to cartilage could be produced with ALA by
illumination at the time of peak cartilage fluorescence (48 h),
but this was not tested as the time interval is so different
from that at which the best sensitisation of mucosa was
found. No long-term studies were undertaken with AlS2Pc
but previous studies were reported by Smith et al. (1993) on
the normal rat trachea using 5 mg kg-' aluminium sulpho-
nated phthalocyanine (AlSPc, a mixture of the mono-, di-,
tri- and tetrasulphonated derivatives) and illumination 1 h
after sensitisation. They showed mucosal and submucosal
changes similar to those reported here, but there was no
damage to cartilage in sections examined as long as 3 months
after PDT.
Thus it would appear that both ALA and AlS2Pc are
potentially suitable for the treatment of mucosal lesions in
the larynx with PDT while preserving the function of deeper
layers. Neither causes damage to cartilage, but both can
damage muscle if used inappropriately. The drug dose and
the time interval from drug to light are important for both.
For ALA, 100 mg kg-' at 3 h produces the desired effects.
Doubling the drug dose leads to muscle damage and reducing
it gives only patchy effects for the same light dose. Other time
intervals were not tested, but peak fluorescence was seen at
this time. Nevertheless, the peak fluorescence levels found
using microfluorimetry provide a measure of the integrated
PPIX levels in each layer (Loh et al., 1993b), although it is
difficult to ascertain exactly how much PPIX is present
intracellularly and how much has been excreted into the
extracellular space. We presume that a treatment time
corresponding to the highest intracellular level would be
optimum and this may precede the time corresponding to the
peak integrated level. Moreover, the ratio between mucosa
and underlying tissues, especially the cartilage, is better at
earlier time points. Bedwell et al. (1992) showed that almost
as much necrosis was produced in normal rat colon 30 min
after ALA as after 4 h, even though peak fluorescence was
seen at 4 h with almost no fluorescence at 30 min. Little data
are yet available on the best times to treat tumours and it will
probably depend on the dose of ALA. Large numbers of
animals with similar laryngeal tumours would be required to
study this formally and no suitable animal model is available,
so it is likely that the answer will come from careful,
empirical, clinical studies, using times in the range 3-6 h as
in other clinical work using systemic ALA (Regula et al.,
1995).
For AlS2Pc, the more important variable is the time
interval from drug to light, as the relative distribution of
sensitiser between mucosa and muscle changes so much. At
1 h, there is far too much muscle damage, but at 24 h
damage is largely limited to the mucosa. We did not study
larger doses ofAlS2Pc, but previous reports of experiments in
the rat bladder (Pope and Bown, 1991) showed that using
larger doses is likely to lead to muscle damage even at 24 h,
and so there is probably a fairly narrow band for the effective
dose of AlS2Pc as there is for ALA. In normal rat stomach
Loh et al. (1992) could not produce any tissue damage with
1 mg kg-' of AlS2Pc and needed higher doses with earlier
irradiation time points. They could not find any conditions
under which they could produce selective mucosal damage in
the stomach using AlS2Pc (although selective mucosal
necrosis was possible with low doses of ALA). These
differences are most likely caused by different PDT thresh-Phdy .rl=y m- - mm ym
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olds in different organs. Higher doses of 5 mg kg-' AISPc
(not AlS2Pc) have been used in other studies (Meyer et al.,
1991; Smith et al., 1993). From the animal data available
(Barr et al., 1990a; Tralau et al., 1987), the best time to treat
tumours is probably 24-48 h after giving AISPc, as this is
the time of greatest ratio of tissue concentration between
tumour and its tissue of origin. A time of 24 h is also
consistent with the present results as the best time for
minimising muscle damage and so this should be the time of
choice in preliminary clinical studies.
It is hoped that clinical studies with AlS2Pc will start in the
next few months. From the experience of others with HpD,
the dose for small animals and patients is about the same
(Grant et al., 1993a), and so as biologically, HpD and AlS2Pc
are similar, a suitable starting dose for clinical work with
AlS%Pc would be 1 mg kg-'. There is not yet enough clinical
data on ALA to make any definitive comment on what dose
would be appropriate for clinical use, although some
preliminary data on its use for the treatment of gastro-
intestinal and oral tumours (Regula et al., 1995; Grant et al.,
1993b) suggest that the appropriate doses may be quite
similar to those used in experiments on small animals. The
tissue distribution of PPIX achieved with oral administration
of ALA in experimental studies on the gastrointestinal tract
was similar to that achieved with intravenous administration
(Loh et al., 1993a). Nevertheless, we feel that the use ofALA
for PDT treatments ofmucosal lesions ofthe larynx might be
preferable with intravenous injection or infusion. The lower
doses of ALA required (half that needed compared with oral
administration, Loh et al., 1993a) could be used more
efficiently owing to the direct uptake in peripheral tissues
avoiding the first-pass hepatic uptake probably encountered
with oral administration. The choice of treatment time could
also be easier. Endoscopic surgery on the larynx is normally
performed under general anaesthesia and oral intake of fluids
within 4 h of anaesthesia is not recommended. Nevertheless,
oral administration of ALA is more convenient for patients
undergoing endoscopy without general anaesthesia. Another
factor is that the maximum dose of ALA that patients can
tolerate by mouth is 60 mg kg-' (owing to hepatotoxicity
after absorption from the gastrointestinal tract) and recent
work suggests that this produces tissue levels of PPIX that
are only just above the threshold required for a PDT effect
(Messman et al., 1995). The current experiments suggest that
100 mg kg-' intravenously is appropriate, but this would be
equivalent to 200 mg kg-' orally, much more than can be
tolerated by this route. A new preparation of ALA that can
be given intravenously is required to assess what the
maximum dose is that can be tolerated by this route before
an appropriate dose for laryngeal tumours can be identified.
This study has identified conditions under which PDT can
be used to produce mucosal necrosis in the normal larynx
with safe healing by regeneration and no unacceptable
changes in the submucosa, muscle or cartilage. Thus, PDT
has potential for treating any lesion of the larynx in which
the abnormal tissue has similar or greater susceptibility to
PDT than the normal mucosa. Current evidence suggests that
dysplasia and all tumours from carcinoma in situ to more
invasive lesions ofthe upper aerodigestive tract are at least as
susceptible as normal mucosa and so would be appropriate
for PDT. Other possible targets would include preneoplastic
lesions such as hyperplastic laryngitis, benign polyps,
recurrences after radiotherapy and conditions such as
laryngeal papillomatosis (Lofgren et al., 1995). However,
for PDT to eradicate lesions in the larynx, it is essential that
the true extent ofdisease is known and that appropriate light
doses can be delivered to all relevant areas, which may not
always be straightforward. Nevertheless, PDT is minimally
invasive and does appear to be safe, so if patients fail other
conventional treatments such as radiotherapy or surgery it
can still be given, which makes it an attractive first option,
particularly in patients whose general condition is poor.
Ackowwedgewnct
D Kleemann and T Mentzel were funded by the German Academic
Exchange Service (DAAD) with additional support from DUSA
Inc, Toronto. SG Bown is funded by The Imperial Cancer
Research Fund. We should also like to thank J Bedwell and G
Buonaccorsi for technical assistance.
Refereuces
ABRAMSON AL, LEVY AS AND HIRSCHFIELD LS. (1990). The
pathologic and thermal effects ofgold vapor laser photodynamic
therapy on the larynx. Arch. Otolaryngol. Head Neck Surg., 116,
687-691.
ABRAMSON AL, SHIKOWITZ Mi, MULLOOLY VM, STEINBERG BM,
AMELLA CA AND ROTHSTEIN HR. (1992). Clinical effects of
photodynamic therapy on recurrent laryngeal papillomas. Arch.
Otolaryngol. Head Neck Surg., 118, 25-29.
BARR H, TRALAU CJ, BOULOS PB, MACROBERT Ai, KRASNER N,
PHILLIPS D AND BOWN SG. (1990a). Selective necrosis in
dimethylhydrazine-induced rat colon tumours using phthalocya-
nine photodynamic therapy. Gastroenterology, 98, 1532-1537.
BARR H, MACROBERT Ai, TRALAU CJ, BOULOS PB AND BOWN SG.
(1990b). The significance of the nature of the photosensitiser for
photodynamic therapy:quantitative and biological studies in the
colon. Br. J. Cancer, 62, 730-735.
BEDWELL J, MACROBERT AJ, PHILLIPS D AND BOWN SG. (1992).
Fluorescence distribution and photodynamic effects of ALA-
induced PPIX in the DMH rat colonic tumour model. Br. J.
Cancer, 65, 818-824.
BERG K, BOMMER IC AND MOAN I. (1989). Evaluation of
sulfonated aluminium phthalocyanines for use in photoche-
motherapy: cellular uptake studies. Cancer Lett., 44, 7-15.
BIEL MA. (1994). Photodynamic therapy and the treatment of
neoplastic diseases ofthe larynx. Laryngoscope, 104, 399-403.
BISHOP S. BEEBY A, KHOO BJ, MACROBERT AJ, SIMPSON MSC AND
PHILLIPS D. (1993). Characterisation of the photochemother-
apeutic agent disulphonated aluminium phthalocyanine using
high performance liquid chromatography of separated compo-
nents. J. Chromatogr., 646, 345-350.
BUGELSKI PJ, PORTER CW AND DOUGHERTY TJ. (1981).
Autoradiographic distribution of HpD in normal and tumor
tissue ofthe mouse. Cancer Res., 41, 4606.
CHAN WS, MACROBERT AJ, PHILLIPS D AND HART IR. (1989). Use
ofcharged couple device for imaging ofintracellular phthalocya-
nines. Photochem. Photobiol., 50, 617-624.
CHAN WS, MARSHALL IF, SVENSEN R, BEDWELL J AND HART IR.
(1990). Effect ofsulphonation oncell and tissuedistribution ofthe
photosensitiser aluminium phthalocyanine. Cancer Res., 50,
4533-4538.
CHATLANI PT, BEDWELL J, MACROBERT AJ. BARR H, BOULOS P,
KRASNER N, PHILLIPS D AND BOWN SG. (1991). Comparison of
di- and tetra- sulphonated aluminium phthalocyanines in normal
rat colon. Photochem. Photobiol., 53, 745-751.
CHEVRETTON EB, BERENBAUM MC AND BONNET R. (1992). The
effect of photodynamic therapy on normal skeletal muscle in an
animal model. Lasers Med. Sci., 7, 103-110.
DE CORBIERE S, OUAYOUN M. SEQUERT C, FRECHE CH AND
CHABOLLE F. (1992). Use of photodynamic therapy in the
treatment of vocal cord carcinoma. Retrospective study 1986-
1992 on 41 cases. In Photodynamic Therapy and Biomedical
Lasers, Spinelli P, Dal Fante M, Marchesini R. (eds) pp. 656-
661. Elsevier Science: Amsterdam.
DIVARIS DSG, KENNEDY JC AND POTTIER RH. (1990). Phototoxic
damage to sebaceous glands and hair follicles of mice after
systemic administration of 5-aminolevulinic acid correlates with
localized protoporphyrin IX fluorescence. Am. J. Pathol., 136,
891 -897.AAd .ic sr~y D Kemrianm et i
FEYH J. (1992). The treatment of larynx papillomas with the aid of
Photodynamic therapy. In Photodynamic Therapy andBiomedical
Lasers, Spinelli P, Dal Fante M, Marchesini R. (eds) pp. 653-
655. Elsevier Science: Amsterdam.
FEYH J, GUTMANN R AND LEUNIG A. (1993). Die photodyna-
mische Lasertherapie im Bereich der Hals-, Nasen-, Ohren
heilklunde. LAryngo-Rhmio-Otol, 72, 273-278.
FEYH J, GOETZ A, MULLER W, KONIGSBERGER R AND KASTEN-
BAUER E. (1990). Photodynamic therapy in head and neck
surgery. J. Photochem. Photobiol., 7, 353-358.
FRECHE CH AND DE CORBIERE S. (1990). Use of photodynamic
therapy in the treatment ofvocal cord carcinoma. J. Photochem.
Photobiol., 6, 291-296.
GLUCKMANN JL AND WEISSLER MC. (1986). Role of photo-
dynamic therapy in the management ofearly cancers ofthe upper
aerodigestive tract. Lasers Med. Sci., 1, 217-220.
GRANT WE, HOPPER C, SPEIGHT P, MACROBERT AJ AND BOWN
SG. (1993a). Photodynamic therapy of malignant and premalig-
nant lesions inpatients with 'fieldcancerization' oftheoralcavity.
J. Laryngol. Otol., 107, 1140-1145.
GRANT WE, HOPPER C, MACROBERT AJ, SPEIGHT PM AND BOWN
SG. (1993b). Photodynamic therapy of oral cancer: photosensiti-
sation with systemic aminolaevulinic acid. Lancet, 342, 147-148.
JUDD MD, BEDWELL J, MACROBERT AJ AND BOWN SG. (1992).
Comparison of the distribution of phthalocyanine and ALA-
induced porphyrin sensitisers within the rabbit uterus. In
Photodynaic Therapy and Biomedical Lasers, Spinelli P, Dal
Fante M, Marchesini R. (eds) pp. 322-326. Elsevier Science:
Amsterdam.
KENNEDY JC AND POTTIER RH. (1992). Endogenous protopor-
phyrin IX, a clinically useful photosensitizer for photodynamic
therapy. J. Photochem. Photobiol. B: Biol, 14, 275-292.
KENNEDY JC, POTTIER RH AND PROSS DC. (1990). Photodynamic
therapy with endogenous protoporphyrin IX: basicprinciples and
present clinical experience. J. Photochem. Photobiol. B: Biol., 6,
143-148.
KLEEMANN D. (1990). Experimentelle Untersuchungen zur Photo-
dynamischen Therapie von malignen Tumoren der Mundh6hle,
des Larynx und Pharynx mit dem Photosensibilisator Methylen-
blau. Laryngo-Rhino-Otol., 69, 437-439.
KLEINSASSER 0. (1987). Tumoren des Larynx unddes Hypopharynx.
pp. 159-164. George Thieme: Stuttgart.
LOFGREN LA, RONN AM, NOURI M, LEE Cl, YOO D AND
STEINBERG BM. (1995). Efficacy of intravenous 5-amino
laevulinic acid photodynamic therapy on rabbit papillomas. Br.
J. Cancer, 72, 857-864.
LOH CS, BEDWELL J, MACROBERT AJ, KRASNER N, PHILLIPS D
AND BOWN SG. (1992). Photodynamic therapy ofthe normal rat
stomach: acomparative study betweendi-sulphonated aluminium
phthalocyanine and 5-aminolaevulinic acid. Br. J. Cancer, 66,
452-462.
LOH CS, MACROBERT AJ, BEDWELL J, REGULA J, KRASNER N
AND BOWN SG. (1993a). Oral versus intravenous administration
of 5-aminolaevulinic acid for photodynamic therapy. Br. J.
Cancer, 68, 41 -51.
LOH CS, VERNON D, MACROBERT AJ, BEDWELL, BOWN, SG AND
BROWN SB. (1993b). Endogenous porphyrin distribution induced
by 5-aminolaevulinic acid in the tissue layers of the gastro-
intestinal tract. J. Photochem. Photobiol. B: Biol., 20, 47-54.
MALIK Z AND LUGACI H. (1987). Destruction oferythroleukaemic
cells by photoactivation ofendogenous porphyrins. Br. J. Cancer,
56, 589-595.
MARRIOTT J. (1968) Regulation of porphyrin synthesis. Biochem.
Soc. Symp., 28,61 -74.
MESSMAN H, MLKVY P, BUONACCORSI G, DAVIES CL, MACRO-
BERT AJ AND BOWN SG. (1995). Enhancement ofphotodynamic
therapy with 5-aminolaevulinic acid-induced porphyrin photo-
sensitisation in normal rat colon by threshold and lighl
fractionation studies. Br. J. Cancer, 72, 589-594.
MEYER M, SPEIGHT P AND BOWN SG. (1991). A study ofthe effects
ofphotodynamic therapy on the normal tissue ofthe rabbit jaw.
Br. J. Cancer, 64, 1093-1097.
MONNIER PH, SAVARY M, FONTOLLIET CH, WAGNIERES G,
CHATELAIN A, CORNAZ P, DEPEURSINGE CH AND VAN DEN
BERGH H. (1990). Photodetection and photodynamic therapy ol
'early' squamous cell carcinomas ofthe pharynx, oesophagus and
tracheo-bronchial tree. Lasers Med. Sci., 5, 149-168.
NUUTINEN PJO, CHATLANI PT, BEDWELL J, MACROBERT Al,
PHILLIPS D AND BOWN SG. (1991). Distribution and photo-
dynamic effect ofdisulphonated aluminium phthalocyanine in the
pancreas and adjacent tissues in the Syrian golden hamster. Br. J.
Cancer, 64, 1108-1115.
PAQUETTE B, ALI H, LANGLOIS R AND VAN LIER VE. (1988).
Biological activities of phthalocyanines VIII. Cellular distribu-
tion in V-79 Chinese hamstercells andphototoxicity ofselectivel)
sulfonated aluminium phthalocyanines. Photochem. Photobiol.,
47, 215-220.
PENG Q, MOAN J, WARERLOE T, NESLAND JM AND RIMINGTON
C. (1992). Distribution and photosensitizing efficiancy ol
porphyrins induced by application of exogenous 5-aminolaevu-
linic acid in mice bearing mammary carcinoma. Int. J. Cancer, 52
433-443.
POPE AJ AND BOWN SG. (1991). The morphological and functional
changes in rat bladder following photodynamic therapy with
phthalocyanine photosensitization. J. Urol., 145, 1064-1070.
REGULA J, MACROBERT AJ, GORCHEIN A, BUONACCORSI GA.,
THORPE SM, SPENCER GM, HATFIELD ARW AND BOWN SG.
(1995). Photosensitisation and photodynamic therapy of oeso-
phageal, duodenal and colorectal tumours using 5-aminolaevu-
linic acid induced protoporphyrin IX: a pilot study. Gut, 36, 67-
75.
RIMINGTON C. (1966). Porphyrin and haem biosynthesis and its
control. Acta Med. Scand., 179, 11 -24.
SMITH SGT, BEDWELL J, MACROBERT Al, GRIFFITHS MH, BOWN
SG AND HETZEL MR. (1993). Experimental studies to assess the
potential ofphotodynamic therapy for the treatment ofbronchial
carcinomas. Thorax, 48, 474-480.
TRALAUCJ, BARR H, SANDEMAN DR, BARTONT, LEWIN MRAND
BOWN SG. (1987). Aluminium sulphonated phthalocyanine
distribution in rodent tumours ofthe colon, brain and pancreas.
Photochem. Photobiol., 46, 777-781.
TRALAU CJ, YOUNG AR, WALKER NPJ, VERNON DI, MACROBERT
AJ, BROWN SB AND BOWN SG. (1989). Mouse skin photosensi-
tivity with dihaematoporphyrin ether (DHE) and aluminium
sulphonated phthalocyanine (AISPc): a comparative study.
Photochem. Photobiol., 49, 305-312.
WOLF P AND KERL H. (1991). Photodynamic therapy in patients
with xeroderma pigmentosum. Lancet, 337, 1613 - 1614.
WUSTROW TPU, JOCHAM D, SCHRAMM AAND UNSOLD E. (1988).
Photodynamische Zerstorung in vitrokultivierter Plattenepithelk-
arzinomzellen ausdem Kopf-Hals-Bereich. Laryngo-Rhiw- Otol.,
67, 532-538.
WUSTROW TPU, SCHRAMM A, JOCHAM D AND UNSOLD E. (1989).
Laserlicht-verursachte Zytotoxizitat kultivierter Plattenepithelk-
arnomHellen aus dem Kopf-Hals-Bereich nach Photosensibili-
sierung. Laryngo-Rhino-Otol. 68, 44-50.